EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy

Kosar Ghasemi

Frontiers in Pharmacology · 11.06.2025 · 16

DOI: 10.3389/fphar.2025.1568664 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.06.2025. Verfasst von Kosar Ghasemi. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, School of Pharmacy, Jundishapur University of Medical Sciences, Ahvaz, Iran. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tiragolumab, a monoclonal antibody (mAb) targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT), represents a novel approach in cancer immunotherapy. TIGIT, an immunological checkpoint receptor, suppresses T cell activation and promotes immune evasion in various cancers. By inhibiting TIGIT, Tiragolumab enhances T cell-mediated anti-tumor immunity, particularly when combined with programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors. This synergy arises from complementary mechanisms, where TIGIT blockade reduces CD155-mediated suppression, amplifying PD-1/PD-L1-driven T cell activation. Phase II and III trials, including the CITYSCAPE trial for non-small cell lung cancer (NSCLC), have shown improved objective response rates (37% vs. 21% with PD-L1 inhibitor monotherapy) and progression-free survival (PFS), with manageable adverse effects. However, the potential of other checkpoint inhibitors, such as Lymphocyte Activation Gene 3 (LAG3), T-cell immunoglobulin and mucin domain-3 (TIM-3), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), remains underexplored compared to TIGIT. This review summarizes TIGIT’s molecular mechanisms, preclinical and clinical data, and limitations, including resistance mechanisms (e.g., upregulation of alternative checkpoints), biomarker development, and the need for broader investigation into alternative inhibitors to optimize combination therapies for personalized, durable cancer treatment.

Schlagwörter

Stichwörter der Autor:innen

TIGITcancercancer immunotherapyimmune checkpoint inhibitor 19tiragolumab

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, School of Pharmacy, Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Cellular and Molecular Research Center, Jundishapur University of Medical Sciences, Ahvaz, Iran.

Zitieren

APA

Ghasemi, K. (2025). Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1568664

Vancouver

Ghasemi K. Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1568664

BibTeX
@article{Ghasemi2025,
  author = {Ghasemi, Kosar},
  title = {Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1568664}
}
Kostenlos starten →